GH Research

GH Research is developing several 5-MeO-DMT based therapeutic mechanisms (inhalation and IV) for the treatment of several disorders (including TRD).

GH Research

The products the company is developing (GH001 and GH002) are in phase I & II and preclinical studies at the moment.

In April 2021, GH Research a total of $125 million in a Series B round. GH Research is registered under the ticker NASDAQ: GHRS. Their stock opened with $16.00 in its Jun 24, 2021, IPO after which they raised an additional $184 million.

Key Staff


Company Information

GH Research Website

October, 2018


B2B B2C Pharmaceutical Biotech

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships


HQ / Office Dublin, Ireland